The Evolution of Bayer AG and Its Recent Financial Analysis

Student Name
Professor Name
Course
Date
Bayer AG
Introduction and Background
Bayer AG is a German-based multinational chemical and pharmaceutical company with a broad area of business operations. The company's current objectives include the business of human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. Founded in 1863 in Barmen by Friedrich Bayer and Johann Friedrich, Bayer's initial purpose was manufacturing and selling of synthetic dyestuffs. Bayer became a joint-stock in 1881 as Farbenfabriken vorm. Friedr. Bayer & Co. and this also marked the first financial foundation expansion for Bayer. For the first 20 years, Bayer's employment size grew from 3 to 300. Bayer spent the next 20 years developing itself with international operations and expanding new fields of business. By 1913, exports generated over 80% of the company's revenues. The scientific laboratory built in Wuppertal Elberfeld facilitated Bayer's industrial research, including the development of the company's first significant product, Aspirin, made its first appearance in the market in 1899. Bayer continued to strengthen its international position by acquiring multiple companies outside of Germany. As of 1913, Bayer's workforce almost reached 10,000, with approximately 1,000 scattered around the world. Bayer soon realized that its current location was too small, which limited its ability for further expansion. As a result, the company acquired large sections of land and relocated to its current headquarter, Leverkusen. Then came World War I, which profoundly devastated Bayer's development. Bayer lost most of its export markets, sales of primary products, and its foreign assets. As a result, the company took a different direction and profited through manufacturing explosives and chemical weapons, including chlorine gas. After the War to regain its initial position, Bayer decided to merge with the other five chemical companies to form IG Farben, the largest single company in Germany. The Allied Control Council eventually seized IG Farben due to its actions during World War II. As a result, Bayer reestablished itself in 1951 and ultimately surpassed the entire IG Farben. Bayer marched its way into the 21st century, and like many other companies, it faced the challenge of globalization.
Bayer AG's Acquisitions
In February 2016, Bayer AG and CRISPR Therapeutics AG joined hands and founded Casebia Therapeutics LLP. The purpose was to develop and commercialize new methods to treat blood diseases like anemia, heart problems, and blindness. This joint venture contributed to the success of Bayer AG to an extent as the company’s new methods got fame the world over and helped many people recover from a variety of illnesses.
In December 2016, the company established BlueRock Therapeutics LP. This company provided its services in the field of regenerative medicines. The goal was to develop induced pluripotent stem cell (iPSC) therapies in order to cure different diseases. As of January 2017, the company generated up to $150 million in revenues due to this project.
Next, in January 2017, Bayer AG announced that it would acquire the Cydectin portfolio in America. For this purpos...